Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients. - Wikidata - awgldk - TriplyDB

Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.

Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.

http://www.wikidata.org/entity/Q37205484

about

Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.

P2860

Q37030260-54D6713C-C051-40D0-A349-86D6068D4CBD

P2860

Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.

http://www.wikidata.org/entity/Q37205484

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@en

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@nl

type

label

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@en

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@nl

prefLabel

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@en

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@nl

P1433

Q37205484-995AF787-5497-4258-AF42-A726114B4DB6

P1476

Q37205484-F4290EF9-148A-428D-B0CD-5C89D6A6960F

P2093

Q37205484-111315BA-D0E7-4761-9EBA-925F56DE1E95

Q37205484-11A3CB4F-BC01-47F2-8F50-5B85E0AB00BE

Q37205484-12EAA986-F7FC-4C41-A732-E00DDF31D815

Q37205484-1B16F4A5-2D09-437B-8B2F-AD68149980AC

Q37205484-253A7173-56B9-4725-9798-CF2F80289CA5

Q37205484-5AEC1448-5DC6-4228-97A3-8649C3C7B9C8

Q37205484-7169603D-F33D-4B2C-9C1B-1206F1A38DA0

Q37205484-74915EE9-CC5D-4F35-A715-232894FA7BD9

Q37205484-A0D4C8E5-72DA-491E-9473-EE314E09A04A

Q37205484-B77697DD-195A-43DE-B5B4-B041CCFCEF7F

P2860

Q37205484-0DFCE460-23D3-4305-8FDB-170BA1A0E151

Q37205484-40EE18C4-932F-4CF7-A685-B561B811C287

Q37205484-4676A81E-17F3-4E3A-AA79-16A8B700B40C

Q37205484-4A848D25-945F-4DAB-A3B4-E6FD0F4F442B

Q37205484-5A5B1728-A521-49B9-BBD6-6458B496022B

Q37205484-5A77E4AC-D055-46C7-BAE0-123C93A65F3B

Q37205484-624429F3-E90B-4260-8DD0-F5A258CC4F3B

Q37205484-6290F422-949C-4BF5-8713-CF6946A583D1

Q37205484-69792E78-235F-4AF0-9843-0228CDBA5A46

Q37205484-985E46BD-BF18-49D9-809A-EA147119E100

P304

Q37205484-B7A0BF07-7DA4-4D69-8DDC-3ADE253C5E32

P31

Q37205484-9F555109-D8EA-4AF1-AB1A-ACE577192A3A

P356

Q37205484-F9677502-0DCC-421D-9660-B10D968B7A1F

P433

Q37205484-4AC59FBB-AA02-402E-AC08-787B6BB0D252

P478

Q37205484-ECE64240-E692-4D84-850D-46DB9604B69E

P577

Q37205484-FEBC1892-8673-431B-AE31-8DBCFC6C9BD7

P5875

Q37205484-61851006-3786-4136-9852-ED135B8B48F3

P698

Q37205484-61B4A268-F92B-45DE-9E71-DE9F306E3BFF

P921

Q37205484-D5385E9A-9E91-4B26-84F5-7A97F1522DBC

P932

Q37205484-33F2B88F-7772-4CCA-A6F9-FA26E54AA231

P356

KJIM.2007.22.3.178

P1433

The Korean journal of internal medicine

P1476

Docetaxel monotherapy as secon ...... all cell lung cancer patients.

@en

P2093

Hyun Jin Park

http://www.w3.org/2001/XMLSchema#string

Ie Ryung Yoo

http://www.w3.org/2001/XMLSchema#string

Jin Hyoung Kang

http://www.w3.org/2001/XMLSchema#string

Keon Hyun Jo

http://www.w3.org/2001/XMLSchema#string

Kyo Young Lee

http://www.w3.org/2001/XMLSchema#string

Kyung Shik Lee

http://www.w3.org/2001/XMLSchema#string

Myung Ah Lee

http://www.w3.org/2001/XMLSchema#string

Yeon Sil Kim

http://www.w3.org/2001/XMLSchema#string

Yeong Seon Hong

http://www.w3.org/2001/XMLSchema#string

Yoon Ho Ko

http://www.w3.org/2001/XMLSchema#string

P2860

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Second-line treatment for advanced non-small cell lung cancer: a systematic review.

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

The safety and efficacy of second-line single docetaxel (75 mg/m²) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy.

Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial.

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

P304

178-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3904/KJIM.2007.22.3.178

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5906824

http://www.w3.org/2001/XMLSchema#string

P698

17939335

http://www.w3.org/2001/XMLSchema#string

P921

P932

2687691

http://www.w3.org/2001/XMLSchema#string